Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
Clinical Trials Arena on MSN7d
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trialChinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...
Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...
US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.
Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC –– Company expects to present data ...
The VEGF/VEGFR-2 pathways are central to angiogenesis ... and pembrolizumab to treat rGBM and triple-negative breast cancer (TNBC) and will further investigate the safety of this combination.
For the study, investigators pitted the HER2-targeted antibody-drug conjugate against Eli Lilly’s VEGFR inhibitor Cyramza ... the FDA approved Enhertu in stomach cancer following prior treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback